PRLD
PRLD
NASDAQ · Biotechnology

Prelude Therapeutics Inc

$2.17
+0.15 (+7.43%)
As of Feb 8, 2:10 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 132.26M 127.36M 112.48M
Net Income 2.80M 2.65M 2.17M
EPS
Profit Margin 2.1% 2.1% 1.9%
Rev Growth +3.8% -1.6% +5.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 48.17M 45.92M 54.82M
Total Equity 75.94M 77.37M 76.22M
D/E Ratio 0.63 0.59 0.72
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 4.42M 4.16M 3.31M
Free Cash Flow 2.17M 2.21M 2.87M